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ABSTRACT
Introduction: Lowe Syndrome, or 
Oculocerebrorenal Dystrophy (OCRL), 
has a recessive inheritance linked to 
X chromosome. It presents cataracts 
and glaucoma, delay in neuropsycho-
motor development, cognitive defi-
cits, and renal Fanconi syndrome. 
Objective: Describe five patients with 
OCRL, attended at Tubulopathy out-
patient clinic. Method: We performed 
a retrospective assessment of 5 male pa-
tient clinical charts of OCRL patients. 
Results: Mean age at first consultation 
was 76.5 and mean follow up interval was 
30.5 months (8-53 months). Symptoms 
and clinical signs included cataracts and 
nystagmus. Neuropsychomotor develop-
ment and weight and height deficits were 
present in whole cases, as well as polyu-
ria, polydipsia, and intestinal constipa-
tion, metabolic acidosis, phosphaturia, bi-
carbonaturia, proteinuria, hypercalciuria, 
hyperuricosuria. Nephrocalcinosis was 
identified in one, renal lithiasis in three, 
and reduced kidney size in two patients. 
We found pathological fractures and ra-
chitism in two, bone rarefaction and delay 
of bone age in all of the patients. One pa-
tient presented a reduction in the rhythm 
of glomerular filtration. Therapeutically, 
all patients received alkali, phosphorus 
and vitamin D reposition in addition to a 
dietary orientation adequate to their needs. 
Conclusion: This study emphasizes the im-
portance of early diagnosis and medico-nu-
tritional follow-up, to avoid complications 
related to metabolic disturbances. 
Keywords: oculocerebrorenal syndrome; 
renal tubular acidosis, rickets; Fanconi 
syndrome.
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INTRODUCTION
Lowe Syndrome (oculocerebrorenal syn-
drome), described for the first time by 
Lowe (1952), is an X-linked pathology 
that is recessively transmitted owing to 
mutations in the OCRL1 gene.1-3 This gene 
is located on the X q25-q26 chromosome, 
which encodes the phosphatidylinositol 
enzyme (4, 5) biphosphate 5 - phospha-
tase present in the Golgi complex.4 There 
are over 88 mutations already described. 
Mutation of this enzyme culminates in 
the intracellular accumulation of its PIP2 
substrate, where PIP2 is a phospholipid 
that plays an essential role in cellular pro-
cesses such as intracellular signaling, pro-
tein trafficking, and polymerization of the 
cytoskeleton actin.4
Oculocerebrorenal syndrome (OCRL) 
is characterized by multi-systemic conge-
nital alterations involving the eyes, central 
nervous system (CNS), and kidneys.5-7
Certain clinical manifestations are usu-
ally present, including congenital cataract 
and glaucoma, global delay in neurop-
sychomotor development (NPMD), hypo-
tonia and hyporeflexia, serious cognitive 
deficits (in approximately 50% of cases), 
and renal tubular abnormalities (Fanconi-
like).8 Convulsive crisis, cryptorchidy, 
and deafness are also found to be asso-
ciated with other ocular alterations, such 
as nystagmus, enophthalmia, and miotic 
pupils.4 Skeletal muscle alterations, such 
as articular hyper-mobility, hip luxation, 
rickets, pathological fractures, and weight 
and height deficits, can occur as a conse-
quence of tubular alterations.9 
The Fanconi syndrome appeared in 
these patients during the first year of their 
lives, and it is primarily characterized by 
generalized aminoaciduria and reduction 
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in urea, phosphate, and bicarbonate re-absorption. 
Proteinuria is always present; however, the intensity, 
the age when it begins, and the rate of evolution with 
accompanying loss of renal function are variable.4 
Since this is an X-linked disorder, the mothers of 
the affected children can present central posterior 
lenticular opacification even though this is normally 
asymptomatic.10 
Early diagnosis is necessary for immediate the-
rapeutic intervention to decrease the likelihood of 
complications.
Although genetic study of Lowe Syndrome is ad-
vanced in study centers, patients in daily clinical prac-
tice are generally diagnosed through clinical manifes-
tations and laboratory tests pertinent to the disease. 
In the light of this, the following is a descriptive study 
of this pathology.
METHODS
Five male patients in the tubulopathy outpatient cli-
nic of the Pediatric Nephrology Department of the 
Department of Pediatrics at UNIFESP-EPM were stu-
died between June 2002 and November 2006.
Clinical, laboratory, and imaging (kidney and uri-
nary tract ultrasound-USG, long bones X-RAY) data, 
as well as fundus examinations, were collected retros-
pectively through the revision of charts.
Patient assessment was based on clinical history, 
physical examination, serial anthropometric mea-
sures, serum and urinary electrolyte levels (sodium, 
potassium, calcium, phosphate, magnesium, chlori-
ne), uric acid, creatinine clearance, venous blood gas 
analysis, and urinalysis. 
The assessment of electrolytes urinary excretion 
was conducted through its relationship in the isolated 
sample with urinary creatinine. Analysis data of phos-
phorus and uric acid were performed via the tubular 
re-absorption rate and excretion fraction, respectively. 
Other complementary analyses were performed 
according to the patient’s needs and availability of la-
boratorial services.
Biochemical measurement of urinalysis test was 
performed via a dipstick reading with a Multistik 
(Bayer), and microscope urinary sediment was 
analyzed through qualified technicians reading. Serum 
electrolyte and urinary dosage in isolated samples we-
re performed in an automated way by the ADVIA 
1650 device (Bayer). Venous blood gas analysis was 
performed by an ABL – 700 Radiometer. All exami-
nations were performed in the Clinical Analysis Lab 
at the Hospital São Paulo. 
Ophthalmologic assessments were performed 
by a team of the Department of Ophthalmology of 
UNIFESP-EPM; imaging exams were conducted by 
the Department of Imaging Diagnosis of UNIFESP-
EPM.
Glomerular filtration rate (GFR) was estimated by 
the creatinine clearance, which was calculated based 
on Schwartz formula11 and classified according to 
KDOQI 2006.12
The following values were used in this study as 
references for urinary excretions in isolated urinary 
samples: calcium/creatinine < 0.2,13,14 uric acid frac-
tional excretion (FE) < 10%,15 and phosphorus reab-
sorption rate > 80%.16
Evaluation of five patients with Lowe syndrome 
allowed us to study clinical, laboratorial, and nutri-
tional evolution under therapeutic treatment propo-
sed for the disorder over the study period. 
In this study, each patient was accompanied by 
a team of pediatric nephrologists and nutritionists. 
According to the literature, all were treated with oral 
supplement of sodium bicarbonate, and 80 – 100 mg/
kg/day of L-carnitine. Three (3/5) used a formula con-
taining phosphorus (Neutrophos K 250 mg P + 14.25 
mEq K / 5 mL), three (3/5) used calcitriol, and four 
(4/5) used an angiotensin converting enzyme inhibi-
tor (captopril 0.5 – 2.0 mg/kg/day). Additionally, all 
consumed a diet in which calories and quantities of 
macro and micro-nutrients were specifically adjusted 
to individual needs.
RESULTS
Table 1 shows the clinical characteristics of the pa-
tients studied related to gender, age at diagnosis, 
follow-up time, presence of cataracts, fractures, ri-
ckets, and delay in NPMD. Age at the first consulta-
tion varied between 2 and 151 months (medium 76.5 
months) with a mean follow-up time of 30.5 months 
(minimum 8 and maximum 53). 
According to the standard of genetic transmission 
(recessively linked to X), all patients were males. Of 
the patients described, only one (patient 5) had a posi-
tive family history with two affected members. 
All children presented a delay in neuropsychomo-
tor development and cataracts at an early age; the 
cataracts can be corrected surgically. Despite early 
treatment, all patients presented a visual precision 
deficit and ocular nystagmus. One of them (patient 
2) progressed with unilateral glaucoma controlled by 
drug treatment and keloid lesion in the contralateral 
cornea that required surgical intervention. Patients 
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1 and 4 presented unilateral amaurosis secondary to 
retinal detachment. One of the mothers presented ca-
taracts at an early age.
The diagnosis was performed based on the clinical 
analysis, phenotype, and complementary exams.
Cataracts, which were bilateral in most cases and 
nystagmus were the main clinical signs in the first 
months of life. The delay in neuropsychomotor deve-
lopment was present in all cases during the first mon-
ths. Appendicular and axial hypotonia were noticed 
in four of the five patients, and mental retardation 
appeared in all, to different degrees. 
All of the patients described presented delays in 
the acquisition of language, and none are literate. 
Four patients out of five do not walk, and one (1/5) 
began to walk at the age of five.
Two patients presented a history of pathological 
fractures, and the X-Ray allowed us to document 
bone rarefaction through simple long bone radiogra-
phy in three, osteoporosis (bone densitometry L2-4 
was – 3 SD) in one, and delay in bone ageing in three 
patients.
It was observed that all patients presented polyu-
ria, polydipsia and intestinal constipation. Of the fi-
ve patients, four (1, 2, 3 and 4) presented unilateral 
cryptorchidy that was corrected surgically.
Laboratory data revealed metabolic acidosis (ve-
nous serum bicarbonate between 16 and 21 with an 
average of 18), urinary pH varying from 6.0 to 8.5, 
phosphaturia, bicarbonaturia, proteinuria, hypercal-
ciuria, and hyperuricosuria. In relation to phosphatu-
ria, it is necessary to highlight that patient number 5 
presented a normal initial phosphaturia; at the end of 
the follow-up period, however, this patient had alrea-
dy presented a decrease in phosphorus re-absorption 
rates. This patient was diagnosed in the first month of 
life, due to a positive family history, when there is rare 
evidence of alterations in renal tubular function.
As demonstrated in table 2, three patients pre-
sented renal lithiasis, one nephrocalcinosis, and two 
had normal ultrasonography for their age during the 
follow-up period.
In table 3, the initial and final nutritional rates of 
each patient are shown. All patients presented weight 
and height deficits as well as small stature. 
To compare the mean nutritional evolution at the 
beginning and end of the follow-up period, paired t-
tests were used. The table below shows the descriptive 
levels (p-values) obtained for each test. No statisti-
cally significant improvement (using a 5% significan-
ce cut-off) in any index was noticed (table 4).
According to table 5, two patients presented a 
decreased GFR during the initial assessment. During 
follow-up period, only one of them (patient 4) sho-
wed a GFR that persisted below the expected range. 
Patient number 5 initially presented a clearance below 
90 mL/min, but this was normal for his age at the 
time of assessment.
For treatment of metabolic disturbances, all pa-
tients received alkali therapy (sodium bicarbonate 
or potassium citrate). Three patients received repo-
sition of phosphorus and active vitamin D in addi-
tion to diets adapted to their needs. All patients used 
L-carnitine (between 80 and 100 mg/kg/day).
DISCUSSION
Lowe syndrome is a rare disease with unknown inci-
dence rates in Brazil. The OCRL syndrome was the 
first human pathology attributed to a defect in the 
inositol phosphatase intracellular signal pathway.17 
Although the main clinical manifestations involve 
CNS, eyes, and kidneys, the expression of the OCRL-1 
Table 1 SUMMARY OF CLINICAL DATA AT ENTRY AND AT THE END OF THE STUDY PERIOD FOR FIVE CHILDREN WITH LOWE SYNDROME 
Patient Gender Initial  Final  Diagnostic  Follow up  Cataract Fracture Rickets Delay Cryptorchidy Audiometry
   age age age time
     (m) (m) (m) (m)            
 1 M 89 142 36 53 Y Y Y Y Right Normal
 2 M 27 62 24 35 Y N Y Y Left Defi cit
 3 M 105 113 104 8 Y Y Y Y Right Normal
 4 M 151 163 17 12 Y N Y Y Right NA
 5 M 2 16 1 14 Y N Y Y N Normal
M = male; Y = yes; N = no; NA = not available; NPMD = delay in neuropsychomotor development; m = months.
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Table 3 NUTRITIONAL FOLLOW-UP 
 Patient  Z - W/H    Z - H/A    Z – W/A    BMI  
   Initial  Final Initial  Final Initial  Final Initial  Final
 1 -3.02  -1.54 -6.39  -6.45 -5.09  -4.01 12.04  13.23
 2 -1.31  -1.49 -6.48  -6.19 -4.76  -4.2 15.11  14.7
 3 -1.72  -0.96 -5.53  -5.6 -3.88  -3.54 13.27  14.37
 4 0.63  1.52 -3.31  -3.49 -2.21  -2.28 16.92  17.93
 5 -1.96  -2.11 -0.88  -1.09 -2.06  -2.22 14.46  14.37
BMI = body mass index; Z - W/H Z = score weight/height; Z-A/I = score height/age; Z - H/A = score weight/age.
Table 2 RENAL DYSFUNCTION IN OCRL 
Patient Urinary Tubular Hypercalciuria Serum  Fósforo phos- Proteinuria Renal 
  pH phosphate  acid phorus (mg/dL)  ultrasonography
 1 8.5 52% Y Increased 2.8 S Nephrocalcinosis +   
        Lithiasis
 2 8.5 74% Y Increased 2.6 S Lithiasis
 3 7 73% Y Increased 2 S Lithiasis
 4 6 68% Y Increased 4.9 S Normal
 5 7 94% Y Increased 5.1 S Normal
Y = yes; N = no; FE = fractional excretion.
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Table 4 NUTRITIONAL FOLLOW-UP
   Means    
Index Initial  Final Value-p
Z-W/H -1.476  -0.916 0.154
Z-H/A -4.518  -4.564 0.633
Z-W/A -3.600  -3.250 0.195
BMI 14.360  14.920 0.171
Table 5 EVOLUTION OF SERUM CREATININE VALUES (mg/dL) AND ESTIMATED CREATININE CLEARANCE (mL/min)
Patient Creatinine Clearance Creatinine Clearance
 (initial)   (fi nal)  
1 0.7 68.3 0.7 77.7
2 0.5 74.2 0.2 225.5
3 0.4 137.5 0.3 185.1
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gene is not restricted to these systems but also includes 
the bladder, testicles, uterus, uterine tube, stomach, 
intestines, liver, pancreas, and spleen. However, the 
involvement of such organs is not clinically evident in 
Lowe Syndrome.18 
Hypotonia, hypo or arreflexia, and progressive 
retardation in neurological, psychological and motor 
development are present during the neonatal period 
in the majority of Lowe Syndrome cases.19 Some re-
searchers report an improvement in the neurological 
deficit with rehabilitation programs, but this finding 
was verified in only two patients. Due to the unfa-
vorable socio-economic status of the majority of the 
population assisted in our service, only those two 
patients are involved in rehabilitation programs.
Cataracts observed during the first months of 
life occurred in 100% of the patients affected and 
are thus considered to be one of the main characte-
ristics of the disease. They should be considered an 
element that corroborates clinical data and suggests 
referral of the patient. Despite the fact that all of our 
patients were male and presented cataracts, rickets, 
and delayed NPMD, the majority (4/5) were diagno-
sed lately. 
Fanconi syndrome is the main renal disorder as-
sociated with Lowe syndrome. This generally occurs 
in the first year of life, producing the main metabolic 
disturbances of hypophosphatemia, hypokalemia, 
metabolic acidosis, hyperuricosuria, proteinuria, 
and polyuria.20 The data observed agree with those 
in the literature. There was no initial detection of 
a metabolic disturbance (except for proteinuria) in 
patient five, but this can be attributed to the early 
age of diagnosis. Metabolic disturbance evolved to 
include phosphaturia during follow-up. 
In addition to the clinical-laboratorial findings 
compatible with alteration of the proximal tubular 
function that we observed in the studied patients, all 
of them presented predominantly alkaline urinary pH 
values and positive urinary anion gaps (Cl < Na + K). 
These findings point to a possible defect in the excre-
tion of hydrogen, which was originally cited by Lowe 
et al.1 The OCRL expression of the distal nephron 
can be responsible for this defect.18 Nephrocalcinosis, 
frequently associated with distal tubular acidosis but 
not to the Fanconi syndrome, is also a characteristic 
of this pathology. According to a report in the lite-
rature, nephrocalcinosis provides further evidence of 
distal nephron involvement18 and was observed in one 
of the studied patients.
Biopsy data in children older than five years 
demonstrated sclerosed, hyalinized, or diffusely 
hypercellular glomeruli with thickened basement 
membrane and interstitial fibrosis. Tubular abnor-
malities varied from minor to severe.17 It is believed 
that there is an anatomical and clinical correspon-
dence between the histopathologic stage and clinical 
manifestations.
According to the literature, evolution is marked 
by a progression to terminal renal failureduring the 
second decade of life.4 Except for one case at stage II 
(KDOQI), all cases described in this work presented 
normal renal function. This can be explained by the 
young age of the studied children. Note that the pa-
tient with the functional deficit is the oldest involved 
in the study. 
In agreement with the literature, we did not ob-
serve significant collateral effects with the medication 
used. 
Chronic acidosis disturbs weight and height deve-
lopment.21 In our individualized nutritional follow-
up, we observed a slightly favorable evolution in the 
majority of the analyzed nutritional parameters after 
a partial or total correction of the hydroelectrolytic 
and acid-base conditions. 
After descriptive analysis of the means and consi-
dering the small size of the sample, however, we ob-
serve a nonsignificant difference between the initial 
and final means of the Z-W/H, Z-W/A, and BMI. It is 
possible that these differences could reach significan-
ce at 5% if the sample size were increased.
It is well known that children in nutritional recu-
peration initially recover weight to further present 
a “catch up” in growth. In this way, we would ex-
pect that the first index, in which we would notice 
recuperation, or at least improvement, is the weight/
height index. This would be followed by weight/age 
and finally height, which would improve the height/
age index. Many patients presented bone deformities 
due to hypophosphatemia and an unfavorable socio-
economic situation that impeded physiotherapeutic 
treatments that minimize such deformities. This sug-
gests an explanation for why there was no difference 
in the height/age index in the studied sample.
There is no specific treatment for this pathology. 
The aim of the treatment is to improve the clinical 
evolution of these patients, minimize the complica-
tions inherent to the disease, and postpone the evo-
lution to terminal renal disease. Metabolic acidosis, 
electrolytic disturbances and rickets should be correc-
ted and ocular pathologies handled surgically. 
It is also necessary to emphasize the importance of 
early diagnosis and genetic counseling to avoid reoc-
currence within the same family. 
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